Insider Selling: Vical Major Shareholder Unloads 200,000 Shares of Stock (VICL)
Vical (NASDAQ:VICL) major shareholder James Singer sold 200,000 shares of Vical stock on the open market in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $1.23, for a total value of $246,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
A number of analysts have recently weighed in on VICL shares. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Vical (NASDAQ:VICL) in a research note to investors on Wednesday, August 14th. They now have a $3.00 price target on the stock, down previously from $6.00. Separately, analysts at Credit Suisse downgraded shares of Vical (NASDAQ:VICL) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, August 13th. They now have a $2.00 price target on the stock, down previously from $5.00. Finally, analysts at Stifel Nicolaus downgraded shares of Vical (NASDAQ:VICL) from a “buy” rating to a “hold” rating in a research note to investors on Monday, August 12th.
Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.35.
Vical (NASDAQ:VICL) traded down 3.76% during mid-day trading on Thursday, hitting $1.28. The stock had a trading volume of 1,695,761 shares. Vical has a 52 week low of $1.17 and a 52 week high of $4.74. The stock’s 50-day moving average is $2.27 and its 200-day moving average is $3.25. The company’s market cap is $111.0 million.
Vical (NASDAQ:VICL) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.11). The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $1.70 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was down 6.3% on a year-over-year basis. On average, analysts predict that Vical will post $-0.41 earnings per share for the current fiscal year.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (NASDAQ:VICL) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.